The role of the ovarian steroidaromatase in pathogenesisof reproductive cycles disorders
L.V. Tarasenko, A.G. Reznikov.
Institute of Endocrinology and Metabolism named afterV.P.Komisarenko, AMS of Ukraine, Kyiv
Abstract
In the rats with regular estrous cycles effects of letrozole, a
steroid aromatase inhibitor, on the enzyme activity in ovarian
tissues and reproductive system condition were studied.
Letrozole was administered per os daily in a dose of 1 mg/kg
b.w. over 10 days. As the result of treatment, 20.5-fold de-
crease in aromatase activity was obtained. All animals have
developed persistent anestrus with vaginal smear patterns being
similar to diestrus. Uterine weights were two-fold less than
that of controls, and ovarian weights increased by one third.
The ovaries contained multiple cystoidal follicles. Results of
the study demonstrate the key role of ovarian steroid aromatase
in letrozole-induced disorders of reproductive cycles. Letrozole
might be recommended for experimental modeling of
reproductive cycle disorders in female rats.
References
- Вундер П.А., Сметанина М.Д. О механизмевозникновения эструса у крыс после трансплан-тации яичников в среду с пониженной температурой// Бюл. эксперим. биологии и медицины. – 1983. –95, № 3. – С.103–105.
- Пищулин А.А., Бутов А.В., Удовиченко О.В.Синдром овариальной гиперандрогении неопу-холевого генеза (обзор литературы) // Пробл.репродукции. – 1999. – № 3. – С. 6–19.
- Резніков О.Г., Сініцин П.В., Тарасенко Л.В.,Полякова Л.І. Нейроендокринні механізми розвиткуановуляторного синдрому гіперандрогенногопоходження у щурів // Фізіол. журн. – 1995. – 41,№ 5–6. – С. 33–37.
- Barraclough C.A. Production of anovulatory, sterilerats by single injection of testosterone propionate //Схема досліду Ароматазна активність, пмоль естрадіолу / годна орган на 1 г тканини на 1 г білкаКонтроль 0,910 ± 0,293 13,53 ± 3,58 654,72 ± 186,30Летрозол 0,069 ± 0,021 0,81 ± 0,23 32,01 ± 8,41Р < 0,02 Р < 0,01 Р < 0,01(М ± m; n=7)Т. 53, № 1 15Endocrinology. – 1961. – 68. – P.62–67.
- Bhatnagar A.S. Review of the development of letrozoleand its use in advanced breast cancer and in the neoadjuvantsetting // Breast. – 2006. – Suppl. 1. – P. 3–13.
- Bhatnagar A.S., Batzl C., Hausler A., Nogues V. The roleof estrogen in the feedback regulation of follicle-stimulat-ing hormone secretion in the female rat // J. SteroidBiochem. Mol. Biol. – 1993. – 47, № 1-6. – P.161–166.
- Bhatnagar A.S., Hausler A., Schieweck K. et al. Highlyselective inhibition of estrogen biosynthesis by CGS20267, a new non-steroidal aromatase inhibitor // Ibid. –1990. – 37, № 6. – P.1021–1027.
- Gradishar W.J. Tamoxifen – what next? // Oncologist. –2004. – 9, № 4. – P. 378–384.
- 9. Haynes B.P., Dowsett M., Miller W.R. et al. Thepharmacology of letrozole // J. Steroid Biochem. Mol.Biol. – 2003. – 87, № 1. – P. 35–45.
- 10. Kafali H., Iriadam M., Ozardali I., Demir N. Letrozole-induced polycystic ovaries in the rat: a new model forcystic ovarian disease // Arch. Med. Res. – 2004. – 35,№ 2. – P. 103–108.
- Odum J., Ashby J. Detection of aromatase inhibitorsin vitro using rat ovary microsomes // Toxicol. Lett. –2002. – 129, № 1–2. – P.119–122.
- Sinha S., Kaseta J., Santner S.J. et al. Effect of CGS20267 on ovarian aromatase and gonadotropin levelsin the rat // Breast Cancer Res. Treat. – 1998. – 48,№ 1. – P.45–51.
|
